

**Search terms:**

#1 MeSH: [Inflammatory bowel disease] explode all trees

#2 Crohn Disease

#3 Crohn

#4 IBD

#5 Ulcerative Colitis

#6 #1 or #2 or #3 or #4 or #5

#7 Corticosteroid\* or Budesonide or Prednisone or Prednisolone or Hydrocortisone or Methylprednisolone

#8 5- ASA or 5-aminosalicylates or Aminosaliclates or Mesalamine or Mesalazine or Sulfasalazine or Aminosalicylic acid

#9 Purine Analogues

#10 Tumor Necrosis Factor-alpha

#11 Tumor necrosis factor inhibitor\*

#12 Immunomodulator\* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or Natalizumab or Vedolizumab or Ustekinumab

#13 MeSH: [Anti-Bacterial Agents] explode all trees

#14 Antibiotic\* or Ciprofloxacin or Metronidazole

#15 MeSH: [Probiotics] explode all trees

#16 Probiotic\* or Prebiotic\* or Supplement\* or Calcium or Acetaminophen or Ibuprofen or Fiber\* or elemental diet or polymeric diet or exclusion diet

#17 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16

#18 #6 and #17

## REFERENCES

- 1 **Akobeng AK**, Miller V, Stanton J, Elbadri AM, Thomas AG. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. *J Pediatr Gastroenterol Nutr* 2000; **30**: 78-84 [PMID: 10630444 DOI: 10.1097/00005176-200001000-00022]
- 2 **Albenberg L**, Brensinger C, Wu Q, Gilroy E, Kappelman M, Sandler R. A diet low in red and processed meats does not reduce the rate of Crohn's disease flares in a randomized controlled trial: results of the food and Crohn's disease exacerbation study (FACES). *Gastroenterology* 2018; **154**: S3 [DOI:10.1053/j.gastro.2017.11.035]
- 3 **Ardizzone S**, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? *Aliment Pharmacol Ther* 1999; **13**: 373-379 [PMID: 10102971 DOI: 10.1046/j.1365-2036.1999.00473.x]

4 **Arnold GL**, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. *Inflamm Bowel Dis* 2002; **8**: 10-15 [PMID: 11837933 DOI: 10.1097/00054725-200201000-00002]

5 **Arora S**, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. *Hepatogastroenterology* 1999; **46**: 1724-1729 [PMID: 10430331]

6 **Bartel G**, Weiss I, Turetschek K, Schima W, Püspök A, Waldhoer T, Gasche C. Ingested matter affects intestinal lesions in Crohn's disease. *Inflamm Bowel Dis* 2008; **14**: 374-382 [PMID: 17932967 DOI: 10.1002/ibd.20295]

7 **Belluzzi A**, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 1996; **334**: 1557-1560 [PMID: 8628335 DOI: 10.1056/NEJM199606133342401]

8 **Belluzzi A**, Campieri M, Belloli C, Boschi S, Cottone M, Rizzello F. A new enteric coated preparation of omega-3 fatty acids for preventing post-surgical recurrence in Crohn's disease. *Gastroenterology* 1997; **112**: A494 [DOI:10.1016/s0016-5085(00)85267-1]

9 **Bhattacharyya S**, Xie H, Dodda A, Varady KA, Feferman L, Halline AG, Hanauer SB, Tobacman JK. Reply to critique of "A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity". *Nutr Healthy Aging* 2019; **5**: 159-163 [PMID: 31922053 DOI: 10.3233/NHA-190068]

10 **Brotherton CS**, Taylor AG, Bourguignon C, Anderson JG. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. *Gastroenterol Nurs* 2014; **37**: 206-216 [PMID: 24871666 DOI: 10.1097/SGA.0000000000000047]

11 **Cezard JP**, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. *Gastroenterol Clin Biol* 2009; **33**: 31-40 [PMID: 19118966 DOI: 10.1016/j.gcb.2008.07.007]

- 12 **Costello S**, Waters O, Bryant R, Katsikeros R, Makanyanga J, Schoeman M. Short duration, low intensity pooled faecal microbiota transplantation induces remission inpatients with mild moderately active ulcerative colitis: a randomised controlled trial. *J Crohn's Colitis* 2017; **11**: S23 [DOI: 10.1093/ecco-jcc/jjx002.035]
- 13 **d'Albasio G**, Paoluzi P, Campieri M, Bianchi Porro G, Pera A, Prantera C, Sturniolo GC, Miglioli M. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. *Am J Gastroenterol* 1998; **93**: 799-803 [PMID: 9625131 DOI: 10.1111/j.1572-0241.1998.228\_a.x]
- 14 **D'Haens GR**, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. *Gastroenterology* 2008; **135**: 1123-1129 [PMID: 18727929 DOI: 10.1053/j.gastro.2008.07.010]
- 15 **D'Haens GR**, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. *J Crohns Colitis* 2010; **4**: 153-160 [PMID: 21122499 DOI: 10.1016/j.crohns.2009.09.007]
- 16 **Dariel I**, Levi Z, Fraser A, Hadad B, Niv Y, Fraser G. Elimination diets in the treatment of mildly active Crohn's disease - results of a randomized controlled trial. *Gastroenterology* 2007; **132**: A506-7 [DOI:10.1016/j.jada.2007.05.218]
- 17 **de Franchis R**, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, Pera A, Vecchi M, Del Piano M, Ferrara A, Belloli C, Piodi L, Framarin L, Astegiano M, Riccioli FA, Meucci G. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. *Aliment Pharmacol Ther* 1997; **11**: 845-852 [PMID: 9354191 DOI: 10.1046/j.1365-2036.1997.00212.x]
- 18 **Dewint P**, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula

closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). *Gut* 2014; **63**: 292-299 [PMID: 23525574 DOI: 10.1136/gutjnl-2013-304488]

19 **Feagan B**, Gasink C, Lang Y, Friedman J, Johans J, Gao L. A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: UNITI-2. *Canadian J Gastroentero Hepato* 2016; 2016 [DOI: 10.1136/gutjnl-2016-312388.7]

20 **Feagan BG**, Anderson F, Radford-Smith GL, Solovyov O, Zurdel-Dillinger S. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of N.O.V.E.L. 4, a phase III multicenter study. *Gastroenterology* 2007; **132**: A103 [DOI: 10.1007/s11725-016-0667-x]

21 **Feagan BG**, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. *N Engl J Med* 2000; **342**: 1627-1632 [PMID: 10833208 DOI: 10.1056/NEJM200006013422202]

22 **Feagan B**, McDonald JWD, Greenberg G, Wild G, Pare P, Fedorak RN. An ascending dose trial of a humaniseda4b7 antibody in ulcerative colitis. *Gastroenterology* 2000; **118**: A874 [DOI: 10.1016/s0016-5085(00)85637-1]

23 **Feagan BG**, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. *N Engl J Med* 2005; **352**: 2499-2507 [PMID: 15958805 DOI: 10.1056/NEJMoa042982]

24 **Feagan BG**, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013; **369**: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]

- 25 **Feagan BG**, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. *Gastroenterology* 2013; **145**: 149-157.e2 [PMID: 23528626 DOI: 10.1053/j.gastro.2013.03.025]
- 26 **Feagan BG**, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI-IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med* 2016; **375**: 1946-1960 [PMID: 27959607 DOI: 10.1056/NEJMoa1602773]
- 27 **Feagan BG**, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. *JAMA* 2008; **299**: 1690-7 [DOI:10.1001/jama.299.14.1690]
- 28 **Florent C**, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). *Eur J Gas Hep* 1996; **8**: 229-233 [DOI: 10.1097/00042737-199603000-00008]
- 29 **Gassull MA**, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL, Richart C, Malchow H, González-Huix F, Esteve M; European Group on Enteral Nutrition in Crohn's Disease. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. *Gut* 2002; **51**: 164-168 [PMID: 12117873 DOI: 10.1136/gut.51.2.164]
- 30 **Ghosh S**, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnanek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study

Group. Natalizumab for active Crohn's disease. *N Engl J Med* 2003; **348**: 24-32 [PMID: 12510039 DOI: 10.1056/NEJMoa020732]

31 **Gordon FH**, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. *Gastroenterology* 2001; **121**: 268-274 [PMID: 11487536 DOI: 10.1053/gast.2001.26260]

32 **Griffiths AM**, Pendley F, Issenman R, Cockram D, Jacobsen K, Kelley MJ. Elemental versus polymeric nutrition as primary therapy of active Crohn's disease: a multi-centre pediatric randomized controlled trial. *J Pediatric Gas Nutrition* 2000; **31**: S75 [DOI: 10.1097/00005176-199610000-00039]

33 **Grogan JL**, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: A double-blind randomized controlled trial with two years follow-up. *Inflammatory Bowel Diseases* 2012; **18**: 246-253 [DOI:10.1002/ibd.21690]

34 **Hanai H**, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. *Clin Gas Hep* 2006; **4**: 1502-1506 [DOI: 10.1016/j.cgh.2006.08.008]

35 **Hanauer S**, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. *American J Gastroentero* 2000; **95**: 1749-54 [DOI: 10.1111/j.1572-0241.2000.02185.x]

36 **Hanauer SB**, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. *Gastroenterology* 2004; **127**: 723-729 [PMID: 15362027 DOI: 10.1053/j.gastro.2004.06.002]

37 **Hanauer SB**, Sninsky CA, Robinson M, Powers BJ, McHattie JD, Mayle JE. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. *Ann Internal Medicine* 1996; **124**: 204-211 [DOI: 10.7326/0003-4819-124-2-199601150-00003]

- 38 **Hawkey CJ**, Dube LM, Rountree LV, Linnen PJ, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. *Gastroenterology* 1997; **112**: 718-724 [PMID: 9041232 DOI: 10.1053/gast.1997.v112.pm9041232]
- 39 **Ito H**, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. *Inflammatory Bowel Diseases* 2010; **16**: 1567-1574 [DOI: 10.1002/ibd.21193]
- 40 **Kamm MA**, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. *Gastroenterology* 2007; **132**: 66-75 [DOI: 10.1053/j.gastro.2006.10.011]
- 41 **Keshteli AH**, Valcheva R, Nickurak C, Halloran BP, vanZanten SV, Kroeker K. Adherence to an "Anti-Inflammatory Diet" for 6 months can decrease fecal calprotectin in ulcerative colitis patients: preliminary findings of a randomized controlled trial. *Gastroenterology* 2016; **150**: S807-8 [DOI: 10.1016/s0016-5085(16)32731-7]
- 42 **Kobayashi K**, Katsumata T, Yokoyama K, Takahashi H, Igarashi M, Saigenji K. A randomized controlled study of total parenteral nutrition and enteral nutrition by elemental and polymeric diet as primary therapy in active phase of Crohn's disease. *Nippon Shokakibyo Gakkai Zasshi* 1998; **95**: 1212-1221 [DOI: 10.1016/s0090-3671(08)70441-5]
- 43 **Korzenik JR**, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. *New Eng J Med* 2005; **352**: 2193-2201 [DOI: 10.1056/nejmoa041109]
- 44 **Leiper K**, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. *Alimentary pharmacology & therapeutics* 2008; **27**: 1233-1239 [DOI: 10.1111/j.1365-2036.2008.03661.x]



- 45 **Leiper K**, Woolner J, Mullan MM, Parker T, van der Vliet M, Fear S. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. *Gut* 2001; **49**: 790–794 [DOI: 10.1016/s0016-5085(00)84470-4]
- 46 **Lémann M**, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. *Gastroenterology* 2005; **128**: 1812–1818 [DOI: 10.1053/j.gastro.2005.03.031]
- 47 **Lichtenstein GR**, Gordon GL, Zakko S, Murthy U, SedghiS, Pruitt R. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. *Alimentary Pharmacology and Therapeutics* 2010; **32**: 990–999 [DOI: 10.1111/j.1365-2036.2010.04438.x]
- 48 **Lichtenstein GR**, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. *Clin Gastroenterol Hepatol* 2007; **5**: 95-102 [PMID: 17234558 DOI: 10.1016/j.cgh.2006.10.025]
- 49 **Lochs H**, Mayer M, Fleig W, Mortensen PB, Bauer P, Genser D. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. *Gastroenterology* 2000; **118**: 264-273 [DOI:10.1016/s0016-5085(00)70208-3]
- 50 **Lomer MC**, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. *Eur J Gas Hep* 2005; **17**: 377–384 [DOI: 10.1097/00042737-200503000-00019]
- 51 **Lomer MC**, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. *Eur J Gas Hep* 2001; **13**: 101–106 [DOI: 10.1097/00042737-200102000-00003]
- 52 **Lorenz-Meyer H**, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A

randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). *Scan J Gas* 1996; **31**: 778–785 [DOI: 10.3109/00365529609010352]

53 **Mahmud N**, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. *Gut* 2001; **49**: 552–556 [DOI: 10.1136/gut.49.4.552]

54 **Mannon PJ**, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D. Anti-interleukin-12 antibody for active Crohn's disease. *New Eng J Med* 2004; **351**: 2069-2079 [DOI: 10.1056/nejmoa033402]

55 **Marteau P**, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomized double blind placebo controlled multicentre study. *Gut* 1998; **42**: 195–199 [DOI: 10.1136/gut.42.2.195]

56 **Moayyedi P**, Surette M, Wolfe M, Taraschi R, Kim P, Libertucci J. A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis. *Gastroenterology* 2014; **146**: S-159 [DOI: 10.1016/s0016-5085(14)60567-9]

57 **Modigliani R**, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. *Gastroenterology* 1996; **110**: 688–93 [DOI: 10.1053/gast.1996.v110.pm8608877]

58 **Mowat C**, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double-blind, randomised controlled trial. *Lancet* 2016; **1**: 273–282 [DOI: 10.1093/ecco-jcc/jjw019.025]

59 **Musch E**, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. *Clin Gas Hep* 2005; **3**: 581–586 [DOI: 10.1016/s1542-3565(05)00208-9]

- 60 **Mutlu E**, Mikolaitis S, Sedghi S, Chakradeo PS, Engen P, Chlipala G. Dietary treatment of Crohn's disease: a randomized, placebo-controlled, double-blinded clinical trial. *Gastroenterology* 2016; **150**: S778 [DOI: 10.1016/s0016-5085(16)32638-5]
- 61 **Nikolaus S**, Rutgeerts P, Fedorak R, Steinhart AH, WildGE, Theuer D. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. *Gut* 2003; **52**: 1286–1290 [DOI: 10.1136/gut.52.9.1286]
- 62 **Oren R**, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I. Methotrexate in chronic active Crohn's disease: a doubleblind, randomized, Israeli multicenter trial. *Am J Gas* 1997; **92**: 2203-2209 [DOI: 10.1038/ajg.2015.61]
- 63 **Oren R**, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. *Gastroenterology* 1996; **110**: 1416–1421 [DOI: 10.1053/gast.1996.v110.pm8613046]
- 64 **Panaccione R**, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S. Briakinumab for treatment of Crohn's disease: results of a randomized trial. *Inflammatory Bowel Diseases* 2015; **21**: 1329-1340 [DOI: 10.1097/mib.0000000000000366]
- 65 **Panés J**, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. *Gastroenterology* 2013; **145**: 766–774 [DOI: 10.1053/j.gastro.2013.06.009]
- 66 **Paramsothy S**, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* 2017; **389**: 1218-1228 [PMID: 28214091 DOI: 10.1016/S0140-6736(17)30182-4]
- 67 **Parikh A**, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. *Inflammatory Bowel Diseases* 2012; **18**: 1470–1479 [DOI: 10.1002/ibd.21896]
- 68 **Pena-Rossi C**, Schreiber S, Golubovic G, Mertz-NielsenA, Panes J, Rachmilewitz D. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis.

*Alimentary Pharmacology Therapeutics* 2008; **28**: 758–767 [DOI:10.1111/j.1365-2036.2008.03778.x]

69 **Pontes C**, Vives R, Torres F, Panes J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. *Inflammatory Bowel Diseases* 2014; **20**: 2004–2012 [DOI: 10.1097/mib.0000000000000166]

70 **Prantera C**, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. *Alimentary Pharmacology Therapeutics* 2006; **23**: 1117–1125 [DOI: 10.1111/j.1365-2036.2006.02879.x]

71 **Prantera C**, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. *Gastroenterology* 2012; **142**: 473–481 [DOI: 10.1053/j.gastro.2011.11.032]

72 **Reinisch W**, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. *Am J Gas* 2008; **103**: 2284–2292 [DOI: 10.1111/j.1572-0241.2008.02024.x]

73 **Romano C**, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo controlled study. *World J Gastroenterology* 2005; **11**: 7118–7121 [DOI: 10.3748/wjg.v11.i45.7118]

74 **Rossen NG**, Fuentes S, van der Spek MJ, Tissen JG, Duflou A, Lowenberg M. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology* 2015; **149**: 110–118 [DOI: 10.1053/j.gastro.2015.03.045]

75 **Rubin D**, Cohen R, Sandborn W, Lichtenstein G, Axler J, Riddell R. Budesonide MMX 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-asas. *Inflammatory Bowel Diseases* 2014; **20**: S1 [DOI: 10.1097/01.mib.0000456697.14546.81]

76 **Rutgeerts PJ**, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. *Gut* 2013; **62**: 1122-1130 [DOI: 10.1136/gutjnl-2011-301769]

77 **Sakurai T**, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. *JPEN* 2002; **26**: 98-103 [DOI: 10.1177/014860710202600298]

78 **Sandborn WJ**, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance I. Natalizumab induction and maintenance therapy for Crohn's disease. *New England J Med* 2005; **353**: 1912-1925 [DOI: 10.1056/nejmoa043335]

79 **Sandborn WJ**, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. *Gastroenterology* 2008; **135**: 1130-1141 [DOI: 10.1053/j.gastro.2008.07.014]

80 **Sandborn WJ**, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *New England J Med* 2012; **367**: 1519-1528 [DOI: 10.1056/nejmoa1203572]

81 **Sandborn WJ**, Travis S, Moro L, Jones R, Gaultille T, Bagin R. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. *Gastroenterology* 2012; **143**: 1218-1226 [DOI: 10.1053/j.gastro.2012.08.003]

82 **Sands BE**, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. *Inflammatory Bowel Diseases* 2007; **13**: 2-11 [DOI: 10.1002/ibd.20014]

83 **Scherl EJ**, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. *Am J Gas* 2009; **104**: 1452-1459 [DOI: 10.1038/ajg.2009.83]

- 84 **Selby W**, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007; **132**: 2313–2319 [DOI: 10.1053/j.gastro.2007.03.031]
- 85 **Smith JP**, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. *Dig Dis Sci* 2011; **56**: 2088–2097 [DOI: 10.1007/s10620-011-1653-7]
- 86 **Sood A**, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. *J Gas* 2002; **37**: 270–274 [DOI: 10.1007/s005350200034]
- 87 **Sood A**, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. *Indian J Gastroenterology* 2000; **19**: 14–16 [DOI: 10.1007/s005350200034]
- 88 **Steinhart AH**, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. *Gastroenterology* 2002; **123**: 33–40 [DOI: 10.1053/gast.2002.34225]
- 89 **Strisciuglio C**, Giannetti E, Martinelli M, Sciorio E, Staiano A, Miele E. Does cow's milk protein elimination diet have a role on induction and maintenance of remission in children with ulcerative colitis?. *Acta Paediatrica* 2013; **102**: e273–8 [DOI: 10.1111/apa.12215]
- 90 **Sutherland LR**, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. *Gastroenterology* 1997; **112**: 1069–1077 [DOI: 10.1016/s0016-5085(97)70117-3]
- 91 **Takagi S**, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. *Alim Phar The* 2006; **24**: 1333–1340 [DOI: 10.1111/j.1365-2036.2006.03120.x]

- 92 **Targan SR**, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. *Gastroenterology* 2007; **132**: 1672–1683 [DOI: 10.1053/j.gastro.2007.03.024]
- 93 **Thia KT**, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. *Inflamm Bowel Dis* 2009; **15**: 17-24 [PMID: 18668682 DOI: 10.1002/ibd.20608]
- 94 **Tilg H**, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. *Gut* 2003; **52**: 1728–1733 [DOI: 10.1016/s0016-5085(03)80305-0]
- 95 **Travis S**, Danese S, Kupcinkas L, Alexeeva O, D'Haens G, Gibson PR. Once-daily budesonide MMX in active mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut* 2014; **63**: 433–441 [DOI: 10.1136/gutjnl-2012-304258]
- 96 **Valentine JF**, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. *Gut* 2009; **58**: 1354–1362 [DOI: 10.1136/gut.2008.165738]
- 97 **Verma S**, Brown S, Kirkwood B, Gjaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. *Am J Gas* 2000; **95**: 735–739 [DOI:10.1111/j.1572-0241.2000.01527.x]
- 98 **Vermeire S**, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet* 2014; **384**: 309-318 [PMID: 24814090 DOI: 10.1016/S0140-6736(14)60661-9]
- 99 **Wildt S**, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with *Lactobacillus acidophilus* La-5 and *Bifidobacterium*

animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. *J Crohn's Colitis* 2011; **5**: 115-121 [DOI: 10.1016/j.crohns.2010.11.004]